KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. (Q27851616)

PubMed

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

Fortunato Ciardiello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Veerle De Vriendt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

Wendy De Roock

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

Sabine Tejpar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

publication date

14 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

863-603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

EGFR antagonists in cancer treatment

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Status of PI3K inhibition and biomarker development in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Nuclear EGFR contributes to acquired resistance to cetuximab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Overexpression of the insulin-like growth factor I receptor in human colon carcinomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Targeting the RAF-MEK-ERK pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(10)70209-6

7 January 2021

10.1016/S1470-2045(10)70209-6

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21163703 AND SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017